# Morepen Laboratories share price today (Morepen Laboratories Ltd, NSE: MOREPENLAB)

> Morepen Laboratories share price today: ₹101.33 at the NSE close on 4 November 2026, up 115.7% in a year. Morepen Laboratories (NSE: MOREPENLAB) is worth ₹5,570 crore, trades at a P/E of 29.5 and has closed between ₹34.17 and ₹133.70 over the past 52 weeks. > Morepen Laboratories Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. MOREPENLAB · Pharma - API & CRAMS · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/morepen-laboratories-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: ₹101.33 (+115.7% in a year)
- P/E: 29.5× (lower than 56% of the last 10 years)
- Revenue (Sep 2026): ₹746 Cr (+81.1% on a year ago)
- Profit (Sep 2026): ₹89.0 Cr (+117.1% on a year ago)
- Operating margin: 16.0% (+9.0 points on a year ago)
- ROCE: 8%, FY26
- ROIC: 13.0%, against a 12.0% cost of capital: +1.0 points

The main question: profits are rising, but only 44% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Morepen Laboratories share price today? Morepen Laboratories Ltd's share price was ₹101.33 at the close on 4 November 2026. It has been rising for 18 weeks. That is 29.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹34 and ₹134, and at that close it sat 67% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 27 weeks in a row. Over the last 11 years the share price moved +275% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Morepen Laboratories this quarter? Three changes stood out: best operating margin in 16 quarters, highest quarterly profit in 16 quarters and highest quarterly revenue in 16 quarters. 1. Best operating margin in 16 quarters Operating margin was 16% in the September 2026 quarter, against 7% a year earlier. 2. Highest quarterly profit in 16 quarters Profit of ₹89 crore in the September 2026 quarter is the highest of the last 16 quarters. 3. Highest quarterly revenue in 16 quarters Revenue of ₹746 crore in the September 2026 quarter is the highest of the last 16 quarters. ## What are Morepen Laboratories' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Morepen Laboratories reported revenue of ₹746 crore, up 81.1% from ₹412 crore a year earlier, and a profit of ₹89.0 crore, up 117.1% from ₹41.0 crore. ### Morepen Laboratories results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹746 crore | ₹412 crore | +81.1% |
| Profit | ₹89.0 crore | ₹41.0 crore | +117.1% |
| Earnings per share | ₹1.62 | ₹0.75 | +116.0% |
| Operating margin | 16.0% | 7.0% | +9.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Morepen Laboratories share price history? Morepen Laboratories closed at ₹101.33 on 4 November 2026, up 115.7% from ₹46.97 a year earlier (7 November 2025) and up 98.1% over five years. Its highest weekly close since March 2016 was ₹133.70 on 1 October 2026. ### Morepen Laboratories share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹113.70 | −10.9% |
| 1 month ago · 1 Oct 2026 | ₹133.70 | −24.2% |
| 6 months ago · 8 May 2026 | ₹45.64 | +122.0% |
| 1 year ago · 7 Nov 2025 | ₹46.97 | +115.7% |
| 3 years ago · 3 Nov 2023 | ₹36.20 | +179.9% |
| 5 years ago · 4 Nov 2021 | ₹51.15 | +98.1% |
| 10 years ago · 4 Nov 2016 | ₹21.80 | +364.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹27.05 | +274.6% |
| Highest weekly close since March 2016, also the 52-week high · 1 Oct 2026 | ₹133.70 | −24.2% |
| Lowest weekly close since March 2016 · 20 Mar 2020 | ₹9.00 | +1,025.9% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹34.17 | +196.5% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (561 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Morepen Laboratories? 4 Nov 2026: Morepen Laboratories closed at ₹101.33, down 10.9% on the week and down 24.2% on the month. Results for July to September 2026: Revenue up 81.1% and profit up 117.1% on a year earlier. ### Earlier

- 18 Sep 2026: ex-date for a dividend of ₹0.20 a share, record date 19 Sep 2026. ## What dividend does Morepen Laboratories pay? Morepen Laboratories paid ₹0.20 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.20% at the ₹101.33 close on 4 November 2026. The last was a dividend of ₹0.20 a share, ex-date 18 September 2026. ### Morepen Laboratories dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 18 Sep 2026 | ₹0.20 | Dividend | 19 Sep 2026 |
| 29 Aug 2025 | ₹0.20 | Dividend | 30 Aug 2025 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 1 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Morepen Laboratories Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 2 of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## Which stock lists is Morepen Laboratories on? Morepen Laboratories is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 5552.365505072784](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Morepen Laboratories profitable? Morepen Laboratories Ltd earned ₹89.0 Cr of net profit in the Sep 2026 quarter, +117.1% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹96.0 Cr. Over 10 years profit has grown 22.1% a year on average. That is 11.9% of the quarter's revenue. The same quarter a year earlier earned ₹41.0 Cr. For the full year, FY26 profit was ₹96.0 Cr (−18.6% on the year before). Why profit moved: revenue changed +81.1% on a year earlier and the margin moved +9.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +127.5% and revenue +31.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Morepen Laboratories make, and is it growing? Morepen Laboratories Ltd reported ₹746 Cr of revenue in the Sep 2026 quarter, +81.1% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 10 years it has grown 14.1% a year on average. The last full year, FY26, came in at ₹1,806 Cr. The last four reported quarters add to ₹2,285 Cr. FY26 revenue was ₹1,806 Cr, −0.3% on the year before. Recent pace: the last four quarters grew +31.5% on average, against 14.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +30.1%, against +13.9% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +90.9%, against +19.7% a year (accelerating). ## How much of every ₹100 of sales does Morepen Laboratories keep? Morepen Laboratories Ltd's operating margin was 16.0% in the Sep 2026 quarter, 9.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 6.0% and 13.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +9.0 percentage points on the year while gross margin changed +13.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Morepen Laboratories' profit turning into cash? Over the last 3 years, 44% of Morepen Laboratories Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹33.0 Cr of operating cash against ₹96.0 Cr of profit. After ₹54.0 Cr of spending on assets, free cash was −₹21.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 44% of profit came in as cash: the cash cycle got 13 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 13 days longer. The next section looks at where the cash is stuck. ## Where does Morepen Laboratories' cash go? Morepen Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 53 days in FY26, up from 40 days in FY21. It spent ₹349 Cr on assets over the last 3 years. Customers take 67 days to pay, and stock sits for 88 days on average. At FY26 sales of ₹1,806 Cr, each day of that cycle ties up about ₹4.9 Cr, so roughly ₹262 Cr is tied up in the business at any time. FY26: customers took 67 days to pay and stock sat for 88 days, about 2.9 months of sales sitting as stock, for a full cycle of 53 days, longer than FY21's 40. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 88 days. Customers pay about 67 days after that. Suppliers are paid at 103 days. Together that makes the 53-day cycle. Spending on assets: ₹349 Cr over the last 3 years, against ₹98.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹22.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Morepen Laboratories' P/E ratio, and how does it compare with its own history? Morepen Laboratories Ltd's P/E is 29.5×, in the middle of its own history: higher than 44% of past readings. Its usual P/E (the middle reading) is 30.8×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −19.5% while the price moved +115.7%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +14.7% a year; about +7.5% a year came from earnings growth and about +7.2 percentage points from the multiple (the market paying more); over 10 years the price moved +16.6% a year; about +24.7% a year came from earnings growth and about −8.1 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Morepen Laboratories business getting better or worse? Morepen Laboratories Ltd's business is getting better. Profit growth hit its low 3 quarters ago at −21.3% and has recovered to +90.9%, with ROCE rising at 18.8%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Morepen Laboratories earn on its capital? Morepen Laboratories Ltd earned a ROCE of 8% in FY26. That is up from a low of 1% in FY14. Its return on capital used (ROIC) is 1.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 5.3% net margin and 0.93× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 5.3% net margin × 0.93× asset turnover × 1.55× leverage (assets divided by equity) ≈ 7.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 13.0% − 12.0% = +1.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 13.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 5.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Morepen Laboratories have too much debt? Morepen Laboratories Ltd has total debt of ₹323 Cr against shareholder equity of ₹1,382 Cr as of Sep 2026, so its debt is 0.23× its equity, which is very little. Year by year, that ratio went from 0.23 in FY22 to 0.17 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Morepen Laboratories shareholding pattern? Foreign institutions raised their stake in Morepen Laboratories Ltd by 1.4 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 3.4% of the company. Promoters moved +0.0 points over the same period, to 35.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +1.4 points over 8 quarters, to 3.4%; Promoters: +0.0 points over 8 quarters, to 35.7%; Domestic institutions: +0.0 points over 8 quarters, to 1.7%. Why the owners changed: foreign institutions drove it (+1.4 points). They raised their stake step by step. ## How far is Morepen Laboratories from balance-sheet trouble? For Morepen Laboratories Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Morepen Laboratories rank in its industry? 62.1 out of 100, rank 7 of 24 in Pharma - API & CRAMS, with 85% of the evidence available. Morepen Laboratories Ltd scores 62.1 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 7. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 31.8 + 9.3 + 8.5 + 12.5 = 62.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Morepen Laboratories compared with? Morepen Laboratories ranks 7 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 62.1 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Morepen Laboratories Ltd this page MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Morepen Laboratories in size? Morepen Laboratories is the 18th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Concord Biotech, Blue Jet Healthcare and Supriya Lifescience. Just below it: IOL Chemicals & Pharmaceuticals, SMS Pharmaceuticals and Solara Active Pharma Sciences. ### Pharma - API & CRAMS companies close in size

1. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) ₹13,031 crore
2. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) ₹9,550 crore
3. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) ₹6,819 crore
4. Morepen Laboratories Ltd ₹6,211 crore
5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) ₹5,215 crore
6. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) ₹4,789 crore
7. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) ₹3,070 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Restaurant Brands Asia Ltd](https://www.sectoralpha.in/stocks/restaurant-brands-asia-ltd) ₹6,249 crore · Quick Service Restaurant - QSR
2. [Onemi Technology Solutions Ltd](https://www.sectoralpha.in/stocks/onemi-technology-solutions-ltd) ₹6,235 crore · Finance - Investment/Others
3. Morepen Laboratories Ltd ₹6,211 crore
4. [DCB Bank Ltd](https://www.sectoralpha.in/stocks/dcb-bank-ltd) ₹6,206 crore · Banks - Private
5. [Nephrocare Health Services Ltd](https://www.sectoralpha.in/stocks/nephrocare-health-services-ltd) ₹6,180 crore · Hospitals/Medical Services

## What else do people ask about Morepen Laboratories? ### What is Morepen Laboratories's share price today? Morepen Laboratories Ltd's share price is ₹101.33, +115.7% over the past year. The whole company is worth ₹5,570 Cr on the market. In the last 52 weeks it traded between ₹34 to ₹134; today it is 67% of the way up from the low, 29.6% above its 200-day average (as of 4 November 2026). ### What were Morepen Laboratories's latest quarterly results? Morepen Laboratories Ltd reported revenue of ₹746 Cr and net profit of ₹89.0 Cr for the Sep 2026 quarter. Revenue rose 81.1% and profit rose 117.1% compared with a year earlier. Earnings per share were ₹1.62. The operating margin was 16.0%, 9.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Morepen Laboratories's market cap? Morepen Laboratories Ltd's market capitalisation is ₹5,570 Cr at a share price of ₹101.33. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Morepen Laboratories performing? Morepen Laboratories Ltd's share price has been rising for 18 weeks. In its latest quarter, revenue rose 81.1% and profit rose 117.1% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 27 weeks running (as of 4 November 2026). ### Will Morepen Laboratories's share price go up? This page does not forecast Morepen Laboratories Ltd's share price. What it shows instead: the share price is ₹101.33, and it has been rising for 18 weeks. Its P/E of 29.5× is higher than 44% of its own last 10 years (as of 4 November 2026). ### Who owns Morepen Laboratories? Promoters own 35.7% of Morepen Laboratories Ltd, foreign institutions 3.4%, domestic institutions 1.7% and the public 59.2% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 1.4 percentage points over 8 quarters (as of 4 November 2026). ### Does Morepen Laboratories have too much debt? No, Morepen Laboratories Ltd has little debt: its debt is 0.17× its equity, and its operating profit is 8 times its interest bill. FY26 borrowings were ₹208 Cr against equity of ₹1,247 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Morepen Laboratories in its business cycle? Morepen Laboratories Ltd's FY26 operating margin was 7.0%, against a 13-year range of 6.0% to 13.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 16.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Morepen Laboratories story? The main question: profits are rising, but only 44% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Morepen Laboratories a stock worth studying right now? What the numbers show: Morepen Laboratories Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.